Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell Carcinoma


Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.

Related Videos
Related Content